The Belgian biotechnology company, Cardio3 BioSciences recently announced its authorization to begin the world’s first phase III clinical trial in regenerative medicine for heart failure in Spain. Spain is the sixth country to have authorized this unique study after the United Kingdom, Belgium, Israel, Serbia and Hungary.
The multicenter, phase III trial will evaluate efficacy and safety of a breakthrough process developed at Mayo Clinic which uses stem cells harvested from a patient’s bone marrow. The stem cells undergo a conditioning treatment that optimizes their repair capacity in heart failure. The treated cells are then injected into the patient’s heart in an effort to restore health in patients suffering from end-stage heart failure.
Read more about this technology and the Mayo Clinic Center for Regenerative Medicine here: http://www.mayo.edu/research/discoverys-edge/regenerating-heart-tissue-stem-cell-therapy